Last updated on February 2018

Safety and Biomarker Study of EPI-589 in Subjects With ALS

Brief description of study

Open label study with EPI-589 and ALS subjects

Detailed Study Description

Open label with 30-day run in phase to establish baseline parameters and a 90-day withdrawal phase to determine duration of treatment response.

Clinical Study Identifier: NCT02460679

Contact Investigators or Research Sites near you

Start Over

Robert Baloh, MD, PhD

Cedar's Sinai
Los Angeles, CA United States
  Connect »

Robert Miller, MD

California Pacific Medical Center
San Francisco, CA United States
  Connect »

Kimberly Goslin, MD, PhD

Providence Brain and Spine Institute ALS Center
Portland, OR United States
  Connect »